UPL gets exclusive access to Flupyrimin for rice in Southeast Asia by collaborating with Meiji
UPL Limited has informed the bourses that its subsidiary has entered into a licence agreement with the Japanese company, Meiji Seika Pharma Co., Ltd. for exclusive access to Flupyrimin for rice in Southeast Asia.
Under the licence agreement, UPL will obtain exclusive rights to develop, register, and commercialise formulations of Flupyrimin for foliar applications in rice in Southeast Asia thereby, expanding the ongoing collaboration between the two companies with this compound.
Earlier in 2018, UPL’s subsidiary and Meiji had entered into an exclusive licensing agreement for UPL to commercialise formulations of Flupyrimin for applications in rice in India. Later in 2020, the two companies had signed a long-term global commercial exclusive agreement (excluding Japan, South Korea & Taiwan and non-exclusive in China) to use Flupyrimin in seed treatment as well as in-furrow applications.
Flupyrimin, discovered by Meiji, is a patented active ingredient and the only AI in the new mode of action subgroup, Pyridylidenes, defined by IRAC in 2021. It is a novel insecticide with unique biological properties, which is effective against major rice pests, such as brown plant hopper and rice stem borer, including those populations resistant to existing insecticides.
With this, the stock of UPL had surged 2 per cent to Rs 687.95 from its previous close of Rs 674.40 during the early morning session on BSE.